This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CREBBP / CREB-binding protein · IHC design guide
Design Immunohistochemistry for CREBBP
Plan CREBBP paraffin IHC around widespread nuclear staining (HPA tissue IHC) and the catalog antibody’s 1:200–1:1000 IHC range (datasheet: M00205-1). Use colon glandular cells as a high-staining reference (HPA tissue IHC), and score cytoplasmic signal separately because UV damage can relocalize CREBBP (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CREBBP Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear in tissue (HPA tissue IHC); cytoplasm annotated (UniProt) | |
| Staining pattern | Widespread nuclear staining across tissue cell types (HPA tissue IHC) | |
| Antigen retrieval | Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen) | |
| Positive control | Cerebellum+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | UV damage can shift CREBBP to the cytoplasm (UniProt) | |
| Regulation | Tissue regulation is unannotated (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope differences unspecified (UniProt) |
Section 1
Recommended CREBBP IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol (datasheet) with a published CREBBP IHC protocol in human bladder cancer tissue (PMC4411067).
| Sample | Paraffin-embedded human tonsil carcinoma tissue; fixative not specified (datasheet A00205-3) |
| Fixation | Image fixative and duration unreported (datasheet A00205-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0, 20 min at 95–98 °C (standard rule: nuclear antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-CREBBP, 1:50-1:200 (datasheet A00205-3) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CREBBP-positive staining in cells in granular layer of cerebellum (HPA tissue IHC: High). HPA tissue profile: Ubiquitous nuclear expression. No signal in the no-primary control. |
💡Decision noteStart with Tris-EDTA pH 9.0 retrieval at 95–98 °C for 20 min (page retrieval rule: nuclear antigen).
Section 2
What Is the Expected CREBBP Staining Pattern?
CREBBP should show predominantly nuclear staining across many cell types in paraffin section IHC; HPA describes a ubiquitous nuclear pattern with Supported reliability and low tissue RNA specificity (HPA: tissue IHC). Its nuclear localization fits its transcriptional coactivator function, although UniProt also records cytoplasmic localization and context dependent movement between compartments (UniProt Q92793: function; subcellular location). CREBBP has no transmembrane segment (UniProt Q92793: topology).
| Nuclear staining in colon glandular cells or cervical squamous epithelial cells. | This matches cell types scored High by HPA (HPA: colon and cervix tissue IHC). Compare nuclei with the counterstain, and assess intensity within the intended cell population rather than treating every cell in a section as equally positive (standard IHC practice). |
| Predominantly membranous staining, or cytoplasmic staining without a convincing nuclear pattern. | Treat this as discordant with the usual tissue IHC pattern and investigate artefact (HPA: ubiquitous nuclear expression; standard IHC practice). Cytoplasmic CREBBP is documented, including after UV damage, so compartment alone cannot prove that an individual signal is false (UniProt Q92793: subcellular location). |
| Strong staining confined to an unexpected cell population while expected nuclei remain unstained. | Consider cross-reactivity or endogenous chromogenic activity and examine controls (standard IHC practice). Tissue context matters: HPA reports High staining in endometrial stromal cells as well as in several epithelial populations, so stromal staining is not inherently anomalous (HPA: tissue IHC). |
| Diffuse color over nuclei, cytoplasm, and surrounding tissue. | A poorly bounded signal is hard to score as CREBBP; assess background with appropriate staining controls (standard IHC practice). HPA's supported tissue result describes nuclear expression and does not validate diffuse section-wide color as a target pattern (HPA: tissue IHC). |
| No nuclear signal in a section expected to provide a strong positive comparison. | First check the assay and tissue control before interpreting absence of CREBBP (standard IHC practice). HPA scores cerebellar granular-layer cells and colon glandular cells High, making them documented comparison populations if present in the study material (HPA: tissue IHC). |
💡Expected CREBBP appearanceCall a result consistent with CREBBP when identifiable nuclei stain in the expected cell population, particularly one scored High by HPA; diffuse section-wide color or isolated membranous signal is suspect (HPA: tissue IHC; standard IHC practice).
| Tissue and cell population | HPA calls tissue IHC expression ubiquitously nuclear but scores particular populations differently: colon glandular cells are High, while skeletal-muscle myocytes and adipocytes are low (HPA: tissue IHC). Interpret intensity against the named cell population, not the tissue label alone (standard IHC practice). |
| Low-staining comparisons | Glial cells in hippocampus, soft-tissue fibroblasts, and bone-marrow hematopoietic cells are listed as low, not negative (HPA: tissue IHC). Weak staining there cannot by itself establish assay failure or specificity (HPA: tissue IHC; standard IHC practice). |
| Compartment and cell state | Nucleoplasm and nuclear bodies are enhanced locations in HPA ICC-IF (HPA: subcellular ICC-IF). UniProt records cytoplasmic localization and context dependent nuclear–cytoplasmic movement (UniProt Q92793: subcellular location). Use the tissue IHC nuclear pattern as the main paraffin-section comparison (HPA: tissue IHC). |
| Antibody evidence | HPA lists Supported IHC staining for HPA055861 and CAB004212 (HPA: antibodies). Its overall tissue IHC reliability is Supported because staining agrees well with RNA expression (HPA: tissue IHC). These summaries support pattern comparison but do not specify performance for every staining condition (standard IHC practice). |
| Isoforms and epitope coverage | UniProt lists 2 CREBBP isoforms and a KIX region, bromodomain, and HAT region (UniProt Q92793: isoforms; domains). The supplied sources do not locate an IHC antibody's epitope, so isoform coverage cannot be inferred from these domain annotations (UniProt Q92793: isoforms; HPA: antibodies). |
| IF/ICC question: what should appear? | Nucleoplasmic and nuclear-body signal is the HPA ICC-IF expectation (HPA: subcellular ICC-IF). That imaging result helps interpret localization, but it is a separate application from chromogenic paraffin-section IHC (HPA: subcellular ICC-IF; tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| Known High population shows no nuclear staining (HPA: tissue IHC). | The tissue IHC expectation and observed result disagree; a workflow failure is possible (HPA: tissue IHC; standard IHC practice). | Check section integrity, antigen retrieval, primary-antibody application, detection reagents, and a concurrently stained positive control before scoring the sample negative (standard IHC practice). No CREBBP-specific retrieval condition or fixation sensitivity is established here (HPA: tissue IHC; UniProt Q92793). |
| Signal is mostly membranous. | A membrane-dominant pattern conflicts with HPA's nuclear tissue pattern and CREBBP's lack of a transmembrane segment (HPA: tissue IHC; UniProt Q92793: topology). | Compare with the counterstain and controls; check whether color follows tissue edges or deposits outside cells, then repeat the assay if the pattern persists (standard IHC practice). |
| Unexpected cells stain strongly, but expected nuclei do not. | Cross-reactivity or endogenous detection activity is possible; some stromal populations are genuine high-staining exceptions (standard IHC practice; HPA: endometrial stroma). | Identify the cells morphologically, compare their HPA population annotation, and inspect appropriate primary-omission and detection controls before attributing signal to CREBBP (HPA: tissue IHC; standard IHC practice). |
| Background obscures nuclear boundaries. | Nonspecific binding or chromogenic detection background may interfere with interpretation (standard IHC practice). | Review blocking, washing, primary-antibody concentration, and detection controls; score only nuclei whose boundaries and cell identity can be judged (standard IHC practice). |
| A low-staining population appears faint or negative. | HPA lists several populations as low rather than negative, so faint signal may fall near the assay's detection limit (HPA: tissue IHC; standard IHC practice). | Compare it with a documented High population stained in the same run, and avoid calling CREBBP absent solely from a weak low-population result (HPA: tissue IHC; standard IHC practice). |
| Cytoplasmic color accompanies nuclear staining. | UniProt allows cytoplasmic CREBBP and describes context dependent redistribution, while HPA's ordinary tissue IHC profile is nuclear (UniProt Q92793: subcellular location; HPA: tissue IHC). | Record nuclear and cytoplasmic components separately, assess whether the cytoplasmic color is cell bounded, and use controls before interpreting redistribution (standard IHC practice). |
Experiment evidence
IHC & IF images showing CREBBP staining
A00205-3 · IHCImmunohistochemistry (IHC) analyzes of CBP (E1528) pAb in paraffin-embedded human tonsil carcinoma tissue at 1:50.showing cytoplasmic and nu
A00205-3 · IHCImmunohistochemistry (IHC) analyzes of CBP (E1528) pAb in paraffin-embedded human lung carcinoma tissue at 1:50.showing cytoplasmic and nucl
M00205-1 · IHCHuman pancreas was stained with anti-CREBBP rabbit antibody
M00205-1 · IHCMouse colon was stained with anti-CREBBP rabbit antibody
A00205-1 · IHCImmunohistochemistry analysis of paraffin-embedded human lung carcinoma tissue, using CBP Antibody. The picture on the right is blocked with
A00205-1 · IFImmunofluorescence analysis of HeLa cells, using CBP Antibody. The picture on the right is blocked with the synthesized peptide.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000005339-CREBBP/tissue/cerebral+cortex#imid_1443668
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000005339-CREBBP/tissue/colon#imid_1443594
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000005339-CREBBP/tissue/liver#imid_16634730
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000005339-CREBBP/tissue/kidney#imid_1443604
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB004212; green = CREBBP, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB004212; green = CREBBP, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CREBBP IHC & IF
🧪Run colon first: glandular cells should stain (HPA: High in colon glandular cells). HPA detects CREBBP in all 45 scored tissues, so there is no HPA-supported negative tissue; use no-primary and isotype controls, and treat any background-only cells on the positive slide as unvalidated internal negatives (HPA: no negative tissue rows; standard IHC practice).
Positive control tissue: Cerebellum (Cells in granular layer, HPA High)
Negative control tissue: None in HPA: CREBBP is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CREBBP in A-431, U-251MG, U2OS, MCF-7, ASC52telo, hTERT-RPE1 (serum starved), KOLF2.1J, U2OS, siRNA 1 (10x), U2OS, siRNA 1 (40x), U2OS, siRNA 2 (10x), U2OS, siRNA 2 (40x), U2OS, scrambled (10x), U2OS, scrambled (40x), NIH 3T3, with annotated localisation: Nucleoplasm (enhanced), Nuclear bodies (enhanced) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control, a concentration-matched rabbit polyclonal IgG isotype control, and CREBBP-knockout material if available as a biological negative (selected-SKU caption: rabbit polyclonal primary and anti-rabbit secondary; standard IHC practice). For colon sections, block endogenous peroxidase and check for endogenous biotin and nonspecific chromogen in gland lumina when using avidin–peroxidase detection (selected-SKU caption: avidin–peroxidase; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or retrieval dependence is reported in the supplied evidence; optimize antigen retrieval empirically for paraffin sections (selected-SKU caption: paraffin IHC; standard IHC practice). The selected A00205-3 caption leaves the fixative unreported, so it does not establish fixation (selected-SKU caption: fixative not stated). Frozen sections are not evaluated here, and the HPA ICC-IF images establish a nucleoplasm and nuclear-body reference without showing that IF is easier (HPA: subcellular ICC-IF summary). The selected A00205-3 tissue-IHC caption documents paraffin sections, but does not specify the fixative (selected-SKU IHC image A00205-3).
HPA tissue IHC evidence for CREBBP
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | Cells in granular layer | High | Protein (IHC) | HPA → |
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Endometrium | Cells in endometrial stroma | High | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: CREBBP is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced CREBBP IHC Tips
Troubleshoot CREBBP staining by checking retrieval, nuclear localisation, controls and scoring before interpreting changes in signal.
What should I adjust when CREBBP staining is weak in paraffin sections?
Use Tris-EDTA pH 9.0 HIER at 95–98 °C for 20 min (page retrieval setting for CREBBP). If nuclear staining remains weak, confirm that sections reached the specified temperature and remained immersed throughout the timed step, then compare runs using the same control section (standard IHC practice). The catalog antibody A00205-3 produced nuclear and cytoplasmic staining in paraffin-embedded human tonsil carcinoma at 1:50, although its image caption does not report retrieval conditions (catalog caption: A00205-3). Assess recovery in intact nuclei against a no-primary control before increasing antibody concentration, since stronger chromogen alone cannot establish specific detection (standard IHC practice).
Could fixation explain weak or uneven CREBBP staining?
Target-specific sensitivity of CREBBP staining to fixative type or duration is unknown from the supplied evidence (catalog caption: A00205-3, fixative unreported). The catalog image identifies paraffin-embedded human tonsil carcinoma but gives no fixative, so it cannot establish a preferred fixation condition (catalog caption: A00205-3). For troubleshooting, compare sections with documented processing histories using the same retrieval, antibody dilution and chromogen development, while examining intact regions away from obvious processing damage (standard IHC practice). Record fixation details alongside nuclear staining intensity and the no-primary result; avoid attributing a difference to fixation until matched material isolates that variable (standard IHC practice).
Should CREBBP staining be nuclear, cytoplasmic or both?
Prioritise nuclear staining when judging CREBBP IHC because tissue profiling reports ubiquitous nuclear expression, while subcellular profiling places it mainly in the nucleoplasm and nuclear bodies (HPA tissue IHC; HPA subcellular). Cytoplasmic signal is biologically possible: UniProt lists both compartments and reports relocalisation under specific conditions, including after UV damage (UniProt Q92793 localisation). The A00205-3 paraffin-section image also describes both nuclear and cytoplasmic staining, without establishing that every cytoplasmic-positive cell is specific (catalog caption: A00205-3). Score nuclear and cytoplasmic compartments separately, compare their distribution with intact tissue morphology, and check any diffuse cytoplasmic colour against the no-primary control (standard IHC practice).
Can this antibody distinguish CREBBP isoforms or modified epitopes?
Do not assign an IHC signal to a particular CREBBP isoform without an antibody epitope map and isoform-specific validation; the supplied record lists 2 isoforms (UniProt Q92793 isoforms). CREBBP contains KIX at residues 587–666, a bromodomain at 1085–1192 and a HAT region at 1323–1700, but the A00205-3 caption supplies no immunogen coordinates (UniProt Q92793 domains; catalog caption: A00205-3). The record also lists modified residues, including phosphorylation and methylation, without showing that either changes this antibody’s staining (UniProt Q92793 modified residues). If staining differs across specimens, compare a second antibody with a documented, distinct epitope before interpreting it as an isoform or modification change (standard IHC practice).
How should I investigate CREBBP localisation with multiplex immunofluorescence?
For a separate IF experiment, pair CREBBP with a marker identifying the cell population under study; HPA reports high staining in colon glandular cells, for example (HPA tissue IHC). Choose spectrally separated fluorophores and assess tissue autofluorescence in an unstained section before assigning a channel to weak CREBBP signal (standard IF practice). CREBBP has no transmembrane segment and is mainly nucleoplasmic or in nuclear bodies, so permeabilisation must allow antibody access to nuclear epitopes (UniProt Q92793 topology; HPA subcellular; standard IF practice). Validate the IF antibody and controls within that application; the A00205-3 paraffin IHC caption does not establish its IF performance (catalog caption: A00205-3).
How can I distinguish CREBBP signal from chromogenic background?
Start with a no-primary section: the A00205-3 image used PBS in place of primary antibody with a biotinylated secondary and avidin-peroxidase detection (catalog caption: A00205-3). Examine whether colour persists in that control, especially over damaged tissue, pigment or tissue edges, before counting stained nuclei (standard IHC practice). Apply an appropriate peroxidase block and inspect background from the detection system; these are general chromogenic IHC steps, not evidence about CREBBP itself (standard IHC practice). If background rises with antibody concentration, titrate around the image’s 1:50 dilution while holding retrieval and chromogen development constant, then judge nuclear contrast against controls (catalog caption: A00205-3; standard IHC practice).
What is a defensible way to quantify CREBBP IHC? ⚠ ANSWER MARKED FOR VERIFICATION
Define the analysed cell population and score nuclear CREBBP separately from cytoplasmic colour, since HPA describes ubiquitous nuclear expression while the catalog image reports both compartments (HPA tissue IHC; catalog caption: A00205-3). For each intact region, record the percentage of positive nuclei and staining intensity, then calculate a nuclear H-score from the intensity categories if that scoring scheme fits the study (standard IHC practice). Normalise counts to the number of eligible nuclei, or report positive-cell density per mm² when tissue area is the denominator (standard IHC practice). Keep section selection, threshold, retrieval and chromogen development consistent, and exclude necrotic or damaged areas using prespecified rules (standard IHC practice).
When does a CREBBP-positive section support a biological conclusion?
A convincing result shows reproducible staining in intact cells, with nuclear signal supported by HPA’s tissue and subcellular profiles (HPA tissue IHC; HPA subcellular). Interpret cytoplasmic staining cautiously: UniProt permits cytoplasmic localisation, and the A00205-3 image shows it, but neither observation validates every cytoplasmic deposit (UniProt Q92793 localisation; catalog caption: A00205-3). Compare staining across the intended cell population and check section edges, necrosis and the no-primary control for artefact or residual endogenous enzyme activity (standard IHC practice). Report compartment and cell type with the score, and avoid inferring CREBBP enzymatic activity solely from chromogenic intensity (UniProt Q92793 function; standard IHC interpretation).
Boster reagents
Best CREBBP / CREB-binding protein IHC Antibodies
Three anti-CREBBP antibodies list IHC and IF applications and human, mouse, and rat reactivity; the supplied images show human and mouse IHC and HeLa IF (catalog applications/reactivity; image captions).
Real IHC data
Anti-CBP (E1528) CREBBP Antibody
Cat # A00205-3
Real IHC data
Anti-CREBBP Rabbit Monoclonal Antibody
Cat # M00205-1
Real IHC data
Anti-CBP CREBBP Antibody
Cat # A00205-1
A00205-3 has IHC images of paraffin-embedded human tonsil and lung carcinoma; A00205-1 has a paraffin-embedded human lung carcinoma IHC image and a HeLa IF image (IHC/IF image captions). M00205-1 has IHC images of human pancreas and mouse colon; all three list human, mouse, and rat reactivity (IHC image captions; catalog reactivity).
Which to pick: For paraffin-section IHC, consider A00205-3: its own human tonsil and lung carcinoma captions specify paraffin embedding and a 1:50 dilution, but do not report the fixative (A00205-3 IHC image captions). For IF/ICC, consider A00205-1 because its own HeLa IF image includes a peptide-blocked comparison; its IHC caption describes paraffin-embedded human lung carcinoma, with fixative unreported (A00205-1 IF and IHC image captions). For human and mouse tissue IHC, M00205-1 offers a monoclonal option with images from both species; rat reactivity is listed for all three SKUs, without a supplied rat IHC image (M00205-1 catalog description and IHC image captions; catalog reactivity and IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q92793 (CBP_HUMAN, CREB-binding protein).
- Human Protein Atlas. CREBBP tissue IHC expression (reliability: Supported).
- Human Protein Atlas. CREBBP subcellular location (ICC-IF): Mainly localized to the nucleoplasm and nuclear bodies..
- Human Protein Atlas. CREBBP antibody validation summary (2 antibodies).
- Upregulated microRNA‑330‑3p promotes calcification in the bicuspid aortic valve via targeting CREBBP. Molecular medicine reports 2020 — PMC7411470.
- Temporal and spatial distribution of histone acetylation in mouse molar development. PeerJ 2025 — PMC11967410.
- Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PloS one 2015 — PMC4411067.
- Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study. Signal transduction and targeted therapy 2026 — PMC13111648.
- PubMed PMID:9238046 — UniProt-cited evidence.
- PubMed PMID:9177780 — UniProt-cited evidence.
- PubMed PMID:8782817 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CREBBP (CREB-binding protein). Expected localisation Nuclear in tissue (HPA tissue IHC); cytoplasm annotated (UniProt). Antigen retrieval: Tris-EDTA pH 9.0 HIER, 95–98 °C, 20 min (rule: nuclear antigen). Validated IHC antibody: A00205-3 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Cerebellum (Cells in granular layer); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human tonsil carcinoma tissue; fixative not specified (datasheet A00205-3); 2. Fixation: Image fixative and duration unreported (datasheet A00205-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in Tris-EDTA buffer, pH 9.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-CREBBP, 1:50-1:200 (datasheet A00205-3); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: UV damage can shift CREBBP to the cytoplasm (UniProt); Isoform / epitope: 2 isoforms; epitope differences unspecified (UniProt); Regulation: Tissue regulation is unannotated (UniProt). Evidence: UniProt Q92793, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm and nuclear bodies., Datasheet A00205-3, PMC4411067. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CREBBP/immunohistochemistry-ihc-guide.